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CDC2‑like (CLK) protein kinase 
inhibition as a novel targeted 
therapeutic strategy in prostate 
cancer
Simon Uzor1,5, Sean R. Porazinski1,6, Ling Li2, Bethany Clark1, Masahiko Ajiro3, Kei Iida3, 
Masatoshi Hagiwara3, Abdullah A. Alqasem4, Claire M. Perks4, Ian D. Wilson 1, 
Sebastian Oltean 2,7* & Michael R. Ladomery1,7* 
Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs 
because of mutations in splice sites or sites that regulate splicing, or because of the altered expression 
and activity of splice factors and of splice factor kinases that regulate splice factor activity. Recently 
the CDC2‑like kinases (CLKs) have attracted attention due to their increasing involvement in cancer. 
We measured the effect of the CLK inhibitor, the benzothiazole TG003, on two prostate cancer cell 
lines. TG003 reduced cell proliferation and increased apoptosis in PC3 and DU145 cells. Conversely, the 
overexpression of CLK1 in PC3 cells prevented TG003 from reducing cell proliferation. TG003 slowed 
scratch closure and reduced cell migration and invasion in a transwell assay. TG003 decisively inhibited 
the growth of a PC3 cell line xenograft in nude mice. We performed a transcriptomic analysis of cells 
treated with TG003. We report widespread and consistent changes in alternative splicing of cancer‑
associated genes including CENPE, ESCO2, CKAP2, MELK, ASPH and CD164 in both HeLa and PC3 
cells. Together these findings suggest that targeting CLKs will provide novel therapeutic opportunities 
in prostate cancer.
The vast majority of human genes are alternatively spliced (> 94%), expressing splice isoforms that often exhibit 
antagonistic  properties1,2. Aberrant alternative splicing contributes to the pathogenesis and progression of 
 cancer3 and plays an essential role in all hallmarks of  cancer4. Dysregulated alternative splicing has even been 
proposed as new a cancer  hallmark5, and is associated with the effectiveness of treatments and the development 
of drug  resistance6.There are multiple mechanisms through which the expression of oncogenic splice isoforms 
can increase. Splice sites can be mutated directly; cryptic splice sites can be activated, and regulatory sequences 
known as exonic or intronic enhancers or silencers can be disrupted. Mutations that affect the pre-mRNA splicing 
machinery are also associated with cancer. SF3b is a heptameric complex and component of the U2 snRNP that 
contacts the intron’s branch site during splicing. Mutations of SF3b are associated with several cancers including 
leukemia and melanoma, and cause disruption to the normal recognition of branch  sites7. The expression of alter-
native splicing regulators can also be altered in cancer, including splice factor proteins and noncoding RNAs that 
regulate alternative splicing. SRSF1 is a well-studied RNA-binding splice factor, and the first to be described as a 
proto-oncogene8–10. As well as splice factors, it is now clear that splice factor protein kinases can also contribute 
to the oncogenic phenotype. These include the SRPKs (SR protein kinases), CLKs (CDC2-like protein kinases), 
DYRK (dual-specificity tyrosine regulated kinase) and PRP4K (pre-mRNA splicing 4 kinase) families. Splice fac-
tor kinases are integrated within established cell signalling networks and modify the localisation and activity of 
splice factors and spliceosome components. They have key roles in tumorigenesis and their activity is associated 
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with response to treatment. We recently demonstrated that inhibition of the splice factor kinase SRPK1 with the 
compound SPHINX reduces prostate cancer xenograft growth through an anti-angiogenic alteration of VEGFA 
 splicing11. Here we have turned our attention to another family of splice factor kinases, the CLKs (CDC2-like).
The human CLK1 gene was first described in  199112. It encodes a 484 amino-acid dual specificity protein 
kinase with the characteristic signature LAMMER sequence in the C-terminal catalytic  domain13. The first 130 
amino-acids consist of a regulatory region required for CLK1 to interact with substrates, including the oncogenic 
splice factor SRSF1. There are four CLK genes in humans, CLK1-4. CLK1, 2 and 4 are ubiquitously expressed, 
whereas CLK3 expression is particularly high in  spermatozoa14. The role of CLK3 in human spermatogenesis 
has not yet been elucidated; interestingly, a CLK-like gene prevents germ cell over-proliferation in Drosophila 
melanogaster15.
The developmental and pathophysiological roles of the four members of the human CLK family are complex. 
CLK1 is involved in adipogenesis where its activity is regulated through Akt-mediated  phosphorylation16. CLK2 
is required for the control of diet-induced thermogenesis in brown adipose  tissue17 and suppresses hepatic 
 gluconeogenesis18. Exercise reduces CLK2 expression in the liver of obese mice, preventing fat build  up19. CLK2 
inhibition may provide benefit for the treatment of Phelan-McDermid  Syndrome20,21, a complex inherited dis-
order caused by deletion of the SHANK3 gene in which affected children experience hypotonia, developmental 
delay, autism and occasional seizures. CLK2 is involved in the regulation of tau alternative splicing, and the 
expression of an inactive isoform of CLK2 is elevated in affected brain areas of sporadic Alzheimer’s  patients22. 
CLK1 inhibition may benefit the treatment of Duchenne’s muscular dystrophy as its inhibition promotes the 
skipping of a mutated dystrophin  exon23. The inhibition of CLKs with small molecule inhibitors could also 
provide avenues for the treatment of infection. To this end, CLK1 inhibitors show promise for the treatment of 
 influenza24, HIV-125 and Plasmodium falciparum infection in  malaria26.
Increasing evidence now links the CLKs to cancer. The CLK2 gene is amplified in a significant proportion of 
breast tumours and its downregulation inhibits cancer cell growth in cell culture and xenografts. Loss of CLK2 
in luminal breast cancer cells leads to the expression of mesenchymal splice variants, such as the skipping of 
exon 11a of ENAH, encoding an actin cytoskeleton  protein27. The targeting of CLK2 with the inhibitor T-025 in 
an allograft model of MYC-driven spontaneous breast cancer resulted in significant anti-tumour effects, includ-
ing the induction of skipped exons, of apoptosis, and growth  suppression28. CLK1 and CLK2 inhibition may 
provide benefit in the treatment of triple-negative breast cancer (TNBC). The compound CC-671, an inhibitor 
of both CLK2 and the dual-specificity protein kinase TTK, blocked the growth of two cell lines and a patient-
derived TNBC  xenograft29. CLK2 also affects cell survival following ionizing radiation. The overexpression of 
CLK2 inhibits cell death induced by doses of two Gray; this effect is dependent on its phosphorylation by  Akt30.
We previously showed that targeting SRPK splice factor kinases in prostate cancer cells could could provide a 
novel therapeutic strategy 11. Here we have targeted CLKs in prostate cancer cells with the benzothiazole TG003, 
a well-established small molecule inhibitor of CLK1 and  CLK431. We find that TG003 has potent anti-tumour 
properties in prostate cancer cells in vitro and in a xenograft model, and that it causes significant changes in the 
alternative splicing of cancer-associated genes.
Materials and methods
Cell culture and reagents. PC3 and PNT2 cells were purchased from ECACC and DU145 cells from 
ATCC. Cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM), plus 2 mM glutamine and 10% 
fetal bovine serum (FBS). The benzothiazole CLK inhibitor TG003 was dissolved in dimethyl sulfoxide (DMSO). 
Unless otherwise specified, cell media and chemicals were purchased from Sigma-Aldrich.
Cell proliferation assays. To count live cells, 3 ×  105 cells were seeded into six-well plates containing 2 ml 
of cell culture medium and treated with 1, 10 and 50 µM TG003. Every 24 h cells were trypsinised and counted 
in a haemocytometer (Neubauer chamber). Trypan blue (0.4% w/v) was used as an exclusion stain.
To measure cell proliferation, 3 ×  105 cells were seeded into six-well plates containing coverslips and serum-
starved in 4 ml of DMEM for eight hours, then replaced with full medium. Cells were treated with 1 µM, 10 µM 
and 50 µM TG003. After 48 h incubation, media was removed and cells were washed twice. Washed cells were 
fixed in 4% (w/v) paraformaldehyde (PFA) for ten minutes and permeabilized in 0.25% (v/v) triton in PBS.
Fixed cells were blocked in 10% FBS-PBS for one hour and incubated overnight at 4 °C with 1:1000 anti-Ki67 
primary antibody (Abcam, Cambridge, UK). Cells were washed three times in PBS before incubation for one 
hour at room temperature with secondary antibody, AlexaFluor 488 goat anti-rabbit (Molecular Probes), diluted 
1:500, followed by washing. Cells were then counterstained with DAPI for four minutes and further washed 
twice before mounting. Images were obtained with an Image Pro Plus (TE 300 Nikon Japan) microscope and 
the percentage proliferation calculated with ImageJ software.
Apoptosis assays. 3 ×  105 cells were seeded in six well plates and treated for up to 72 h with 1 µM, 10 µM 
and 50 µM TG003. Media was removed and replaced with caspase-3/7 green detection reagent (Thermofisher 
Scientific, as per manufacturer instructions) and placed in a 37 °C incubator for 45 min. Images were obtained 
at Fluor 488 green channel with an Image Pro Plus microscope. The percentage of caspase 3/7 positive cells was 
determined using ImageJ software.
Scratch assays. A pipette tip guided by a clean glass slide was used to make a straight-line scratch in a con-
fluent prostate cancer cell line lawn in six well plates. Floating scratched cells were gently removed. A Lumascope 
(Labtech International, USA) was used to record images for 2 h. ImageJ was used to analyse the extent of scratch 
closure in both controls and TG003-treated cells.
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Transwell cell migration and invasion assays. For cell invasion measurements, PC3 cells were serum-
starved for eight hours and subsequently treated for 48 h with TG003. Matrigel (Sigma-Aldrich, 7.9 mg/ml) was 
diluted with serum-free DMEM and 100 µl of the mixture was added into transwell inserts in 24-well plates. 
Matrigel was solidified overnight at 37 °C and then 500 µl of DMEM containing 10% FBS was added to the lower 
chamber as chemoattractant, while 300 µl of serum-free DMEM containing 1.0 ×  105cells was added to the top 
chamber and plates were incubated for 24 h at 37 °C. The media was removed and cells were washed twice in 
PBS and subsequently fixed in 4% (w/v) PFA at room temperature for ten minutes. Non-invasive cells inside the 
insert were removed with a cotton swab. Cells were permeabilized in absolute methanol for 20 min at room tem-
perature after being washed twice in PBS. The insert was cut and inverted onto a glass slide and incubated with 
Hoechst (ThermoFisher Scientific) for 1 h. Invasive cells were counted using an Image Pro Plus microscope. For 
the cell migration assay the same method was used, but inserts were not coated with matrigel.
siRNA knockdown of CLK1. 5 ×  105 PC3 cells were seeded in six well plates with antibiotic-free growth 
medium and allowed to settle overnight. siRNA (control (sc-37007) and CLK1 (sc-60404), Santa Cruz USA) 
and lipofectamine (RNAiMAX Fisher Scientific) were mixed in Optimem medium as per manufacturer instruc-
tions. siRNA was added to cells topped up with 1 ml Optimem (Thermofisher Scientific) and incubated for 4 h 
at 37 °C. Next 2 ml of antibiotic-free DMEM was added and cells grown for 48 h. Cells were lysed with standard 
RIPA buffer including a protease inhibitor cocktail. Proteins were quantified using a standard Bradford assay and 
examined via SDS PAGE.
Immunofluorescence assay. 3.0 ×  105cells were seeded and treated with varying concentrations of TG003 
on clean cover slips in six well plates. Cells were washed three times with warm PBS and fixed in 4% (w/v) PFA. 
Cells were washed three times again, permeabilized in 0.25% (v/v) triton-PBS for 10 min and blocked in 10% 
FBS/PBS for an hour. E-cadherin (24E10 rabbit polyclonal. Cell Signalling Technology) and vimentin (sc-6260 
mouse monoclonal, Santa Cruz, USA) primary antibodies were diluted 1:150 and 1:400 respectively in 10% 
FBS-PBS and incubated overnight at 4 °C. After PBS washes, donkey anti-rabbit AlexaFluor-568 for E-cadherin 
(1:750, Molecular Probes) and anti-mouse AlexaFluor-488 for vimentin (1:1000, Molecular Probes) were applied 
in 10% FBS-PBS at room temperature for one hour. Cells were washed with PBS and counterstained in Hoe-
chst (ThermoFisher Scientific) for 10  min, followed by mounting of coverslips. Images were obtained using 
fluorescence microscopy (Image ProPlus, TE 300 Nikon Japan) using a 60 × objective and analysed with ImageJ 
software.
Generation of stable CLK1 overexpressing cells. PC3 cells were transfected using FuGene® HD Trans-
fection Reagent (Promega). 3 µg of pAM92 CLK1-expressing plasmid provided by Prof. Masatoshi Hagiwara, or 
empty vector (p3xFLAG-CMV-14, Sigma-Aldrich) were diluted in 100 µl Opti-MEM I reduced serum medium 
(Thermofisher, Gibco). 6 µl of the FuGene® HD Transfection Reagent was pipetted directly into the medium 
containing diluted plasmid to form the transfection complex, and then the complex was mixed and incubated 
at room temperature for 15 min. The transfection complex was added to cells and the wells were swirled to 
ensure even distribution. The cells were incubated for 72 h before splitting to T25 flasks. Stable transfectants 
were selected using 500 µg/ml Geneticin (Thermofisher, Gibco) and CLK1 overexpression verified by western 
blotting.
An Alamar Blue (resaruzin, ThermoFisher) proliferation assay was performed on the stably transfected cells, 
following the manufacture’s protocol. PC3, PC3 EV or PC3 CLK1 cells were seeded in 96-well plate at 10,000 cells 
per well and then treated with either control (DMSO) or 10uM TG003 the next day. After 48 h treatment, medium 
was refreshed with serum free media containing 10% Alamar Blue in each well and incubated at 37℃, including 
no-cell control wells as blank. Fluorescence (excitation of 560 nm, and emission at 590 nm) was measured at 
three hours in each well using a SpectraMax M2e Plate Reader (Molecular Devices). The proliferation rate was 
calculated as following: percentage difference between treated and control cells = FI 590 of TG003/FI 590 of con-
trol *100. The data were analysed by Prism using one-way ANOVA. Six repeats were applied for each treatment.
Xenograft analysis. One million PC3 cells were subcutaneously injected into each right flank of CD1- 
nude mice, 12 mice in total (two month old mice, obtained from Charles River Laboratories). Tumour diam-
eters were measured by caliper two times per week. TG003 (corresponding to 50 µM final concentration in the 
mouse) and vehicle control were injected intraperitoneally two times a week when tumour size reached 3 mm 
× 3 mm, 6 mice per treatment group. Mice were culled when control tumours size reached 12 mm in one direc-
tion and tumours were extracted, imaged and weighed. Tumour volumes were calculated using the formula 
‘volume = [(length + width)/2] × length × width’. Quantitation of the tumour volumes were analysed by Two-way 
ANOVA using Prism 6 (GraphPad Software, Inc.). All animal experiments were conducted in accordance with 
UK legislation and with local ethical committee approval (Animal Welfare & Ethical Review Board- University 
of Exeter). We confirm that all animal experiments were carried out in compliance with the ARRIVE guidelines.
Western blotting. Determination of protein concentration was performed using a Bradford assay as per 
manufacturer’s instruction. A standard protein concentration curve was generated using Fluostar Optima, BUG 
Labtech, UK. 20 µg protein samples were prepared in standard Laemmli buffer (at a 1:1 ratio). Protein samples 
were separated using standard SDS-PAGE 10% acrylamide gels. Wet transfer to a PVDF membrane was per-
formed in standard ice-cold transfer buffer, transferring for 2 h at 50 V. Membranes were blocked in 5% bovine 
serum albumin and probed overnight with 1:5000 primary antibodies, CLK1 (Sigma-Aldrich R1471-1S) and 
pan-phospho SR protein (mAb1H4, Insight Biotech. sc-13509). After washing three times in TBST buffer, suita-
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ble secondary antibodies (1:15,000 Licor anti-rabbit) were applied (two hours at room temperature), followed by 
TBST washing. Following chemiluminescence (Luminata forte, Millipore Ltd), membranes were imaged using 
an Odyssey imaging platform (LI-COR, USA).
mRNA sequencing (RNA‑Seq) analysis. RNA-Seq data from SRA ID: SRP075278 (SRR3616963, 
SRR3616964, SRR3616967, and SRR3616968)32 were used for the analysis. Sequence reads with average Phred 
quality scores under 17, or derived from rRNA, tRNA, snRNA, or snoRNA, and those from repetitive elements, 
identified in Repbase  database33, were omitted from the dataset. Quality-controlled mRNA-seq reads were 
mapped to the human genome sequences (hg19) with STAR (ver. 2.4.1d)34, and analyzed with rMATS (ver. 
4.0.2)35. Ensembl annotation ver. GRCh37.75 was used for the  calculation36. Following the calculation, alterna-
tive splicing (AS) events which passed the following criteria were processed as significant AS events; FDR < 0.1, 
related reads ≥ 10 in either of splicing forms, |dPSI|≥ 0.05. We then listed splicing events which affect “productive 
forms”, defined as an alternative mRNA isoform providing CDS for intact protein  products37. Splice isoforms 
that encode translational products in the UniProt database were sorted out as productive forms. Gene ontology 
(GO) analysis for TG003-susceptible events was conducted using metascape  server38.
Reverse transcription‑coupled polymerase chain reaction (RT‑PCR). HeLa and PC3 cells were 
treated with DMSO (0.1%) or TG003 (20 µM) for 24 h, and then total RNA was extracted using direct-zol RNA 
miniprep kit (Zymo Research, Irvine, CA, USA), and reverse transcription (RT) was performed with Prime 
Script RTase (Takara Bio Inc., Shiga, Japan). RT products were then applied for PCR with ExTaq DNA pol-
ymerase (Takara Bio Inc.). Primers used for RT-PCR were as follows: oAM441 (5′-GGA ACT AAA AAC TGC 
TCG TATGC-3′) and oAM442 (5′-CTC AGG CTT TCC GTA AGG TG-3′) for CENPE exon 38 splicing, oAM421 
(5′-GTG GAC AAG CCA GTG CTA CC-3′) and oAM422 (5′-ACA GCA GAC TTA GGA GTA TATAC-3′) for MELK 
exon 13 splicing, oAM423 (5′-AGA ACC CCA GAA TAT CGA AG-3′) and oAM424 (5′-ACG TGG TAA CTA TGC 
TCG GT-3′) for ASPH exon 6 splicing, oAM425 (5′-ACC GAG CAT AGT TAC CAC GT-3′) and oAM426 (5′-CTA 
CAA TTA CCT GTG AAT CT-3′) for ASPH exon 8 splicing, oAM427 (5′-AGT TAG TGA TTG TCA AGT GG-3′) 
Figure 1.  Effect of TG003 on cell proliferation and apoptosis. (A) PC3 and DU145 prostate cancer cell lines 
were treated with 1, 10 and 50 µM TG003. Viable cells were counted at 24, 48, and 72 h following treatment 
(trypan blue assay). Untreated and DMSO controls are included. (B) The proportion of Ki67-positive 
proliferating cells was measured in PC3 and DU145 prostate cancer and in PNT2 normal prostate epithelium 
cells. (C) The percentage of apoptotic cells was measured via caspase 3/7 staining following 48 h of exposure to 
TG003. N = 3 repeats in all experiments. **p < 0.01; ***p < 0.001.
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:7963  | https://doi.org/10.1038/s41598-021-86908-6
www.nature.com/scientificreports/
and oAM428 (5′-AAT GAA ACT GGC TGC ATC AAAG-3′) for CD164 exon 5 splicing, oAM429 (5′-TCG TGT 
TGG TTC TGC CAC AT-3′) and oAM430 (5′-ACC AGT CGT CTT GCA ATG CG-3′) for ESCO2 exon 9 splicing, 
oAM433 (5′-GCA GTC CGC ATT CAA AGA GC-3′) and oAM434 (5′-TTT ATG TGT GTC AAT TAC TACAG-3′) 
for CKAP2 exon 3 splicing, and oAM13 (5′-CCA ACC GCG AGA AGA TGA CC-3′) and oAM14 (5′-AGC TTC 
TCC TTA ATG TCA CG-3′) for ACTB. Percent spliced-in (PSI) for RT-PCR products was calculated by (inclusion 
product)/(inclusion product + skipping product)), according to densitometric intensities normalized by indi-
vidual molecular weights.
Results
The benzothiazole CLK inhibitor TG003 reduces cell proliferation and induces apoptosis. We 
selected the benzothiazole TG003, a well-characterised CLK inhibitor. TG003 was originally developed in Prof. 
Masatoshi Hagiwara’s laboratory and first described in  200431. TG003 is a small molecule inhibitor, with low 
nanomolar  IC50 values for CLK1 and its close homologue CLK4 (15-20 nM)31. We treated PC3 (established from 
a bone metastasis of a grade IV prostate cancer) and DU145 cells (derived from a CNS metastasis of a pros-
tate adenocarcinoma), both hormone-independent cell lines, and for comparison PNT2 immortalised normal 
prostate epithelium cells with a single dose of 1 µM, 10 µM and 50 µM TG003 for up to 72 h. We confirmed 
the previously reported ability of TG003 to reduce SR protein  phosphorylation31 (Supplementary Figure S1A). 
In both prostate cancer cell lines 1 µM TG003 reduced cell proliferation. The effect was more evident at 10 and 
50 µM where cells continued to divide in the initial 24 h but then declined in number markedly (Fig. 1A). Next, 
we measured the cell proliferation marker Ki67 following 48-h exposure to TG003 with the same range of con-
centrations (Fig. 1B). The percentage of Ki67-positive declined with increasing TG003 concentrations. At 50 µM 
TG003, only a third of cells were Ki67-positive. The normal prostate epithelium cell line PNT2 appeared less 
sensitive to TG003, as the percentage of Ki67-positive cells declined at a slower rate.
Previous reports suggest that inhibitors of CLKs and SPRKs can increase  apoptosis39. We therefore investi-
gated the effect of TG003 on apoptosis by measuring activated caspase 3/7 48 h after a single TG003 dose. In all 
three cell lines TG003 caused a noticeable increase in apoptosis, albeit less markedly in the PNT2 cells (Fig. 1C).
TG003 reduces cell migration and invasion. Previous reports suggest that CLKs can influence cell 
migration and invasion. CLK2 inhibition changes the expression and alternative splicing of EMT-associated 
genes in breast  cancer27, and the activation of the splice factor SPF45 following its phosphorylation by CLK1 
promotes cancer cell line migration and invasion of ovarian cancer  cells40. We examined the effect of TG003 on 
Figure 2.  Effect of TG003 on scratch closure, cell migration and invasion. (A) 30 µm scratches were applied 
to confluent cell monolayers and allowed to close over 72 h. PC3 and DU145 cells were treated with 50 µM 
TG003. (B) Cell migration and invasion were measured using a transwell assay following treatment of PC3 cells 
with 1, 10 and 50 µM TG003. (C) Following treatment of PC3 and DU145 cells with 1, 10 and 50 µM TG003, 
E-cadherin and vimentin expression was determined by immunohistochemistry; with Hoechst counterstain. 
N = 3 repeats in all experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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the ability of cells to close a 30 µm gap (scratch assay, Fig. 2A). The gap was closed after 72 h by both PC3 and 
DU145 cells, but this was substantially slowed down by 50 µM TG003. Treatment with 10 µM TG003 resulted 
in an intermediate effect (data not shown). We then used a transwell (Boyden) assay to measure cell migration 
and cell invasion. Both migration and invasion of PC3 cells was significantly reduced by 10 µM of TG003, with a 
more marked effect at 50 µM TG003 (Fig. 2B). Similar results were obtained with DU145 cells (data not shown). 
These results suggest that CLK activity helps to promote a metastatic phenotype. Consistent with this hypothesis, 
we examined the expression of E-cadherin (associated with an epithelial phenotype) and vimentin (associated 
with a mesenchymal phenotype). In both PC3 and DU145 cells we observed that TG003 caused a clear upregula-
tion of E-cadherin in parallel with a reduction in vimentin expression (Fig. 2C).
Knockdown of CLK1 confirms the effect of TG003. The benzothiazole TG003 is most effective against 
CLK1 and  CLK431; however, like other kinase inhibitors, it exhibits cross-reactivity with other kinases including 
CLK2 and DYRK1A. In order to confirm that the effect of TG003 on proliferation, apoptosis and cell migra-
tion was due to CLK inhibition we knocked down CLK1 in PC3 cells using siRNA (Fig. 3A). We observed that 
CLK1 knockdown significantly reduced the number of Ki67-positive cells (Fig. 3B) and doubled the percentage 
of apoptotic cells (Fig. 3C). We performed a scratch closure assay and observed that CLK1 knockdown signifi-
cantly reduced the rate of scratch closure (Fig. 3D). In summary, the knockdown of CLK1 had the same effect 
as TG003.
To provide additional confirmation that TG003′s effect on cell proliferation is due to CLK1 inhibition, we 
generated stable CLK1-overexpressing PC3 cells (Supplementary Fig. S1B) and measured sensitivity to TG003. 
PC3 cells stably transfected with the empty vector (EV) and with a CLK1-expressing vector were seeded into 
96-well plates (10,000 cells/well). After 24 h, cells were treated with 10 µM TG003. We counted cell numbers for 
five days following TG003 treatment. The rate of increase in cell numbers was significantly diminished in both 
TG003-treated parental and empty vector (EV) PC3 cells, whereas there was no difference between untreated 
and TG003-treated CLK1-overexpressing cells (Fig. 4). These results indicate that the overexpression of CLK1 
renders PC3 cells less sensitive to TG003.
Inhibition of xenograft growth by TG003. Having established that TG003 has a strong effect on PC3 
proliferation in vitro, we tested the effectiveness of TG003 in vivo on PC3 xenografts. PC3 cells grow vigorously, 
are highly invasive and well suited for xenograft  experiments41. We injected one million cells subcutaneously 
into the flanks of nude mice. When tumours reached 3 × 3 mm in diameter, a solution of TG003 calculated 
Figure 3.  CLK1 knockdown confirms the effect of TG003. (A) siRNA directed against CLK1 was transfected 
into PC3 cells. CLK1 and GAPDH signals are shown. The knockdown was quantified from N = 3 repeats (right 
panel). The effect of CLK1 knockdown was determined on cell proliferation via Ki67 staining (B); apoptosis 
with caspase 3/7 staining (C) and on scratch closure (D). N = 3 repeats in all experiments. ns, p > 0.05; *p < 0.05; 
**p < 0.01; ***p < 0.001.
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to give 50 µM final concentration in the mouse was injected intraperitoneally twice a week. After 29 days the 
untreated tumours reached the maximum permitted size of 12 mm and the experiment was terminated. The 
TG003 treatments clearly prevented the xenografts growing and the volumes of the tumours in treated animals 
did not increase (Fig. 5). Other than the clear inhibition of tumour growth, the injection of mice with TG003 
bi-weekly did not cause any obvious adverse effects.
RNA‑Seq analysis of the effect of TG003 treatments. To understand the mechanisms that underpin 
growth suppression and apoptotic induction following TG003 treatment in PC3 cells, we searched for TG003-
targeted alternative splice events. By analyzing the RNA-Seq datasets for previously TG003-treated HeLa  cells32, 
we identified 332 exon-skipping events and 286 exon-inclusion events as TG003 target events (Table 1). The most 
frequent alternative splicing events affected by TG003 were skipped exons (supplementary Figure S2A). Among 
332 exon-skipping events, 270 events occurred in exons for productive forms of mRNAs, leading to in-frame 
deletion or production of truncated protein due to a premature termination codon (Fig. 6). In concordance 
with growth suppressive effects obtained through TG003 treatments, gene ontology (GO) analysis of TG003-
responsive alternative splicing events revealed that cell division (GO:0051301), cell cycle (R-HAS-1640170), and 
DNA replication (GO:0006260) were among the most enriched terms (supplementary Figure S2B; for a compre-
hensive list, see Supplementary Figure S3). We subsequently validated the RNA-Seq analysis results by RT-PCR 
in HeLa and PC3 cells, for genes previously reported as oncogenic or malignancy factors, including centromere 
protein E (CENPE), establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2), cytoskeleton 
associated protein 2 (CKAP2), maternal embryonic leucine zipper kinase (MELK), aspartate beta-hydroxylase 
(ASPH), and CD164, transmembrane cell adhesion molecule (Fig. 7). All of the exons we examined showed con-
sistent changes confirming the RNA-Seq analysis results in both HeLa and PC3 cells, with 7/7 in HeLa and 5/7 
in PC3 cells exhibiting ≥ 5.0 of ΔPSI (Fig. 7), indicating that TG003-targeted splice events are largely conserved 
between HeLa and PC3 cells.
Figure 4.  Stable CLK1 overexpression reduces TG003 sensitivity. 10,000 cells were seeded in 96-well plates and 
a single dose of 10 µM TG003 added after 24 h. Cells were counted every 24 up to 144 h (Alamar Blue assay); 
DMSO alone and TG003-treated. (A) Wild-type (WT) cells; (B) PC3 cells stably transfected with empty vector 
(EV); (C) PC3 cells stably transfected with a CLK1-expressing vector; (D) combination of the three. N = 3, 
****p < 0.001, two-way ANOVA.
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Discussion
Interest in the CDC2-like (CLK) splice factor kinases has grown steadily as they are increasingly implicated in 
a wide range of developmental and pathological processes including prostate cancer. Our previous work on the 
splice factor kinase SRPK1 in the prostate cancer context demonstrated that its inhibition may set the scene for 
novel  treatments41. We found that the inhibition of SRPK1 exhibits a potent anti-angiogenic effect by reduc-
ing the expression of the pro-angiogenic splice isoform of VEGF-A, whose expression is increased by SRSF1, 
an oncogenic splice  factor42 and SRPK1 and CLK1 substrate. We therefore decided to investigate the potential 
of targeting CLKs in prostate cancer cells. We selected the benzothiazole TG003, a readily available and well-
established CLK1 and CLK4  inhibitor31. We applied it to two well-studied prostate cancer cell lines, PC3 and 
DU145; and for comparison, normal prostate epithelium (the PNT2 cell line).
Figure 5.  Effect of TG003 on xenograft growth. One million PC3 cells were injected subcutaneously into 
cohorts of six CD1-nude mice and tumour volumes measured over a period of 29 days, comparing vehicle 
control versus 50 µM TG003. (A) Image of the excised tumours; (B) tumour volumes measured in in  mm3 and 
(C) tumour weight in mg. Tumour sizes were statistically different, two-way ANOVA. **p < 0.01; ****p < 0.0001.
Table 1.  List of validated TG003-responsive alternative splice events 32. The seven top hits are shown, listing 
the gene symbols and names, the nature of the altered splicing event, the event ID, and the validation of the 
ΔPSI in both HeLa and PC3 cells.
Gene symbol Gene name TG003-dependent event Event ID Validation (ΔPSI) HeLa cells Validation (ΔPSI) PC3 cells
CENPE Centromere protein E Inclusion, exon 38 25664 Success (8.9) Success (22.7)
ESCO2 Establishment of sister chromatid cohesion N-acetyl-transferase 2 Skipping, exon 9 41800 Success (4.4) Success (5.6)
CKAP2 Cytoskeleton associated protein 2 Skipping, exon 3 82737 Success (5.9) Success (1.9)
MELK Maternal embryonic leucine zipper kinase Skipping, exon 13 83190 Success (33.3) Success (25.8)
ASPH Aspartate beta-hydroxylase Skipping, exon 6 2109 Success (11.5) Success (15.2)
ASPH Aspartate beta-hydroxylase Skipping, exon 8 2108 Success (6.5) Success (4.0)
CD164 CD164 molecule Skipping, exon 5 82773 Success (6.9) Success (10.2)
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We found that TG003 convincingly reduced cell proliferation. Consistent with a previous report that CLK 
splice factor kinase inhibition can induce  apoptosis39, we observed a clear increase in apoptosis by TG003 in all 
three cell lines. We then examined the effect of TG003 on cell biology. TG003 strongly suppressed their growth 
following bi-weekly injections of TG003 (that result in an approximate concentration of 50 µM in the mouse). 
We observed an increase in E-cadherin and a decrease in vimentin expression consistent with a reversal of EMT. 
Having observed the effect of TG003 on prostate cancer cells in vitro, we performed a xenograft experiment. The 
PC3 xenografts grew rapidly; however, TG003 strongly suppressed their growth following bi-weekly injections 
of 50 µM TG003. The mice did not appear adversely affected by multiple TG003 treatments.
Given these findings we performed an RNASeq analysis to understand the pathways through which TG003 
might be exerting its potent effect on prostate cancer cell growth. We exploited a dataset obtained from a previ-
ous RNASeq analysis of TG003-treated HeLa  cells32 and identified 332 exon-skipping and 286 exon-inclusion 
events. We focused on a set of genes previously reported to be associated with oncogenic or malignant processes. 
CENPE plays a major role in chromosome segregation in M-phase, and TG003 promotes inclusion of exon 38, 
resulting in reduced protein  expression33. RT-PCR confirmed this splicing change in treated HeLa and PC3 cells. 
ESCO2 is a cohesion regulator that contributes to cancer cell  proliferation43. We confirmed induced skipping of 
exon 9 that results in in-frame deletion of 49 amino acids at the carboxy-terminal. CKAP2 is involved in ovarian 
cancer tumorigenesis through FAK-ERK pathway and a potential prognostic marker of HER2-negative luminal 
type breast  cancer44. TG003 treatment induced skipping of exon 3 introducing a premature termination codon. 
MELK (maternal embryonic leucine zipper kinase) is an oncogene that is upregulated in high-grade prostate 
 cancer45. TG003 induced exon 13 skipping removing 41 critical amino acids. ASPH is reported as a malignant 
factor in hepatocellular carcinoma, glioma, and pancreatic  cancer46–48, and its targeting reduces proliferation 
and invasion of prostate cancer cells through Notch signalling  modulation49. RT-PCR confirmed that TG003 
induced skipping of exon 6 and 8, resulting in in-frame deletion of 44 and 20 amino acids, respectively, within the 
ASPH amino-terminal region. The sialomucin CD164 promotes Akt/mTOR signaling and known as a malignant 
factor in various  cancers50. TG003 promoted skipping of exon 5 to induce in-frame deletion of 20 amino acids. 
Collectively, our results demonstrate that TG003 treatment induces deletion or truncation of oncogenic and 
malignancy-associated gene products by impairing their alternative splicing regulation.
There is currently a significant worldwide effort to develop specific, highly and pharmacologically effective 
inhibitors of oncogenic splice factor kinases including the  CLKs51–54. In summary, we show that the benzothiazole 
Figure 6.  Effect of TG003 on protein structure caused by alternative splicing events. Diagrams of protein 
structures are shown, indicating the effect of the alternative splicing events detailed in Table 1.
10
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7963  | https://doi.org/10.1038/s41598-021-86908-6
www.nature.com/scientificreports/
CLK inhibitor TG003 potently inhibits prostate cancer cell growth in vitro and in vivo. TG003 reduces cell pro-
liferation, increases apoptosis, reverses EMT marker expression and reduces cell invasion. Further research is 
now needed to develop clinically viable CLK inhibitors.
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